In-Hospital influenza vaccination to prevent cardiorespiratory events in the first 45 days after acute coronary syndrome: A prespecified analysis of the VIP-ACS trial-Reference-Cited by-同舟云学术

In-Hospital influenza vaccination to prevent cardiorespiratory events in the first 45 days after acute coronary syndrome: A prespecified analysis of the VIP-ACS trial

Published:2024-01 Issue:3 Volume:42 Page:496-504
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Fonseca Henrique Andrade R.^ORCID,Zimerman André^ORCID,Monfardini Frederico^ORCID,Guimarães Hélio Penna,Pedrosa Rodrigo P.,Patriota Rodrigo de Lemos S.,Couto Patriota Tarcya L.G.,Passos Luiz Carlos Santana,Dall'Orto Frederico Toledo Campo^ORCID,Hoffmann Filho Conrado Roberto^ORCID,Nascimento Bruno Ramos^ORCID,Baldissera Felipe Antônio,Pereira Cesar A.C.,Caramori Paulo Ricardo Avancini^ORCID,Andrade Pedro Beraldo,Okoshi Marina Politi^ORCID,Polanczyk Carisi Anne,Silveira Fabio Serra,Villacorta Aline Sterque,Nicolau José Carlos,Rizzo Luiz V.,Berwanger Otávio

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference35 articles.

1. Acute coronary syndromes;Bergmark;Lancet,2022

2. Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction;Pilgrim;Am Heart J,2016

3. One-year outcome after percutaneous coronary intervention for acute coronary syndrome - an analysis of 20,042 patients from a japanese nationwide registry;Sawano;Circ J,2021

4. Myocardial infarction accelerates atherosclerosis;Dutta;Nature,2012

5. Acute myocardial infarction after laboratory-confirmed influenza infection;Kwong;N Engl J Med,2018